Mercurius K O, Morla A O
Department of Pathology, MC 1089 Committee on Cancer Biology, University of Chicago, S Maryland Ave, Chicago, IL, USA.
BMC Cell Biol. 2001;2:18. doi: 10.1186/1471-2121-2-18. Epub 2001 Aug 20.
The first type III repeat of fibronectin is known to be involved in fibronectin matrix assembly, and recombinant proteins from this type III repeat can inhibit cell proliferation, tumor metastasis and angiogenesis. We have analyzed the way rat aortic smooth muscle cells (RASMCs) interact with a recombinant protein encompassing a C-terminal portion of the first type III repeat of fibronectin (protein III1-C).
Cells are able to adhere to and spread on III1-C coated on a dish. Both beta1 integrins and cell surface heparan sulfate proteoglycans serve as receptors for III1-C. For example, cell attachment to III1-C is partially inhibited by agents that block beta1 integrins or by heparin. Complete inhibition of cell attachment is seen only when integrin blocking agents are combined with heparin. Affinity chromatography revealed the binding of proteins that likely represent the integrin beta1 and alpha5 submits to a III1-C column. Cell adhesion to III1-C results in robust ERK1/2 activation that is blocked by integrin-blocking agents. In addition, cell adhesion to III1-C and ERK1/2 activation by III1-C are both inhibited by heparan sulfate but not by chondroitin sulfate. Moreover, heparitinase treatment, but not chondroitinase treatment of RASMCs results in reduced cell adhesion and ERK1/2 activation. Affinity chromatography experiments demonstrated that 35SO4-labeled cell surface heparan sulfate proteoglycans bound specifically to III1-C.
The results suggest that the 1st type III repeat of fibronectin contains a previously unrecognized cell adhesion domain that stimulates robust ERK1/2 activation in RASMCs. Cells interact with this domain through cell surface heparan sulfate proteoglycans and integrins, and both classes of receptors are required for optimal cell adhesion and ERK1/2 activation.
已知纤连蛋白的第一个III型重复序列参与纤连蛋白基质组装,并且来自该III型重复序列的重组蛋白可抑制细胞增殖、肿瘤转移和血管生成。我们分析了大鼠主动脉平滑肌细胞(RASMCs)与包含纤连蛋白第一个III型重复序列C末端部分的重组蛋白(蛋白III1-C)相互作用的方式。
细胞能够黏附在培养皿上包被的III1-C上并在其上面铺展。β1整合素和细胞表面硫酸乙酰肝素蛋白聚糖均作为III1-C的受体。例如,细胞对III1-C的黏附可被阻断β1整合素的试剂或肝素部分抑制。仅当整合素阻断剂与肝素联合使用时,细胞黏附才会完全被抑制。亲和层析显示可能代表整合素β1和α5亚基的蛋白质与III1-C柱结合。细胞对III1-C的黏附导致强大的ERK1/2激活,这被整合素阻断剂所阻断。此外,细胞对III1-C的黏附以及III1-C对ERK1/2的激活均被硫酸乙酰肝素抑制,但不被硫酸软骨素抑制。而且,用硫酸乙酰肝素酶处理RASMCs而非用硫酸软骨素酶处理,会导致细胞黏附及ERK1/2激活减少。亲和层析实验表明,35S标记的细胞表面硫酸乙酰肝素蛋白聚糖特异性结合III1-C。
结果表明,纤连蛋白的第一个III型重复序列包含一个先前未被识别的细胞黏附结构域,该结构域可刺激RASMCs中强大的ERK1/2激活。细胞通过细胞表面硫酸乙酰肝素蛋白聚糖和整合素与该结构域相互作用,并且这两类受体对于最佳的细胞黏附及ERK1/2激活都是必需的。